Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl

NCT01081132 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

314

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention-Deficit/Hyperactivity Disorder

Interventions

DRUG: Extended-release Guanfacine Hydrochloride
OTHER: Placebo

Sponsor

Shire